GR1000849B - Αμφιρεγκουλινη:μια νεα διλειτουργικη ρυθμιστικη της αναπτυξης γλυκοπρωτεινη & μεθοδοι παρασκευης. - Google Patents

Αμφιρεγκουλινη:μια νεα διλειτουργικη ρυθμιστικη της αναπτυξης γλυκοπρωτεινη & μεθοδοι παρασκευης.

Info

Publication number
GR1000849B
GR1000849B GR890100037A GR890100037A GR1000849B GR 1000849 B GR1000849 B GR 1000849B GR 890100037 A GR890100037 A GR 890100037A GR 890100037 A GR890100037 A GR 890100037A GR 1000849 B GR1000849 B GR 1000849B
Authority
GR
Greece
Prior art keywords
growth factor
cells
promoting
amphiregulin
glycoprotein
Prior art date
Application number
GR890100037A
Other languages
English (en)
Other versions
GR890100037A (en
Inventor
G James Bradley
L Vicki Mcdonald
Greg Plowman
Mohammed Shoyab
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/297,816 external-priority patent/US5115096A/en
Application filed by Oncogen filed Critical Oncogen
Publication of GR890100037A publication Critical patent/GR890100037A/el
Publication of GR1000849B publication Critical patent/GR1000849B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

Περιγράφεται ένας νέος ρυ?μιστικός της ανάπτυξης του κυττάρου παράγων ονομαζόμενος αμφιρεγκιουλίνη. Αυτή η εξόχως υδρόφιλη γλυκοπρωτείνη, έχουσα ένα μέσο μοριακό βάρος 22,500 daltons, δείχνει ασυνή?ιστη βιολογική δραστικότητα. Η αμφιρεγκιουλίνη είναι ένας διλειτουργικός, ρυ?μιστικός της ανάπτυξης του κυττάρου παράγων που δείχνει ισχυρή ανασταλτική δραστικότητα στη σύν?εση DNA σε νεοπλαστικά κύτταρα, προάγοντας εν τούτοις την ανάπτυξη ορισμένων κανονικών κυττάρων. Η εφεύρεση βασίζεται, εν μέρει, στην ανακάλυψη ότι MCF-7 κύτταρα, όταν υφίστανται κατεργασία με τον παράγοντα προαγωγής όγκου, την 12-τετραδεκανοϋλ-φορβόλη-13-οξεική (ΤΡΑ), εκφράζει και εκκρίνει δύο διάκριτες εν τούτοις ισοδύναμες λειτουργικά μορφές αμφιρεγκιουλίνης. Αυτές οι δύο μορφές είναι συντακτικά ταυτόσημες και ακριβώς ομόλογες, εκτός του ότι η κολοβωμένη μορφή έχει έλλειψη ενός αμινοτερματικού εξαπεπτιδίου που βρίσκεται στη μεγαλύτερη μορφή. Το γονίδιο αμφιρεγκιουλίνης έχει διακλαδω?εί και χρησιμοποιη?εί για να κατασκευάσει πλασμίδια που κατευ?ύνουν την έκφραση βιοδραστικής αμφιρεγκιουλίνης σε μετασχηματισμένα Escherichia coli κύτταρα. Μία ευρεία ποικιλία χρήσεων για αμφιρεγκιουλίνη περικλείεται από την παρούσα εφεύρεση συμπεριλαμβανομένης της ?εραπείας τραυμάτων και καρκίνων. ω
GR890100037A 1988-01-25 1989-01-25 Αμφιρεγκουλινη:μια νεα διλειτουργικη ρυθμιστικη της αναπτυξης γλυκοπρωτεινη & μεθοδοι παρασκευης. GR1000849B (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14832788A 1988-01-25 1988-01-25
US18188488A 1988-04-15 1988-04-15
US07/297,816 US5115096A (en) 1988-04-15 1989-01-17 Amphiregulin: a bifunctional growth modulating glycoprotein

Publications (2)

Publication Number Publication Date
GR890100037A GR890100037A (en) 1990-01-31
GR1000849B true GR1000849B (el) 1993-02-17

Family

ID=27386678

Family Applications (1)

Application Number Title Priority Date Filing Date
GR890100037A GR1000849B (el) 1988-01-25 1989-01-25 Αμφιρεγκουλινη:μια νεα διλειτουργικη ρυθμιστικη της αναπτυξης γλυκοπρωτεινη & μεθοδοι παρασκευης.

Country Status (24)

Country Link
US (1) US5830995A (el)
JP (1) JPH02104596A (el)
CN (1) CN1038126A (el)
AT (1) AT399720B (el)
AU (1) AU623109B2 (el)
BE (1) BE1004201A5 (el)
CH (1) CH681080A5 (el)
DE (1) DE3902157A1 (el)
DK (1) DK29989A (el)
ES (1) ES2016432A6 (el)
FI (1) FI890312A (el)
FR (1) FR2628109B1 (el)
GB (1) GB2214185B (el)
GR (1) GR1000849B (el)
HU (1) HUT52545A (el)
IE (1) IE61146B1 (el)
IL (1) IL89033A (el)
IT (1) IT1229504B (el)
MY (1) MY104980A (el)
NL (1) NL8900178A (el)
NO (1) NO177788C (el)
NZ (1) NZ227729A (el)
SE (1) SE504554C2 (el)
YU (1) YU16989A (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262298A (en) * 1989-05-12 1993-11-16 The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University Method to assess the ability of a substance to inhibit or stimulate keratinocyte autocrine factor production
EP0444961A1 (en) * 1990-03-02 1991-09-04 Bristol-Myers Squibb Company Her3: A novel EGF receptor homolog
EP0559769B1 (en) * 1990-10-16 2001-02-07 The Children's Medical Center Corporation Heparin binding mitogen with homology to epidermal growth factor (egf)
US5302706A (en) * 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
US6235884B1 (en) 1993-06-15 2001-05-22 Scios Nova, Inc. Heparin binding mitogen with homology to epidermal growth factor (EGF)
US5633147A (en) * 1994-03-08 1997-05-27 Human Genome Sciences, Inc. Transforming growth factor αH1
CA2237543A1 (en) * 1995-12-22 1997-07-03 Innogenetics N.V. New form of amphiregulin, methods for producing and using the same and compositions comprising the same
US6852506B1 (en) 1996-04-10 2005-02-08 Human Genome Sciences, Inc. Extracellular/epidermal growth factor-like protein
US5948889A (en) * 1996-05-21 1999-09-07 Case Western Reserve University Compositions and methods for screening antimicrobials
WO1998046746A1 (en) * 1997-04-11 1998-10-22 Human Genome Sciences, Inc. Extracellular/epidermal growth factor like protein
US20060276629A9 (en) * 1999-12-17 2006-12-07 Hildebrand William H Purification and characterization of soluble human HLA proteins
US20050003483A1 (en) * 2000-10-10 2005-01-06 Hildebrand William H. Comparative ligand mapping from MHC class 1 positive cells
DE60138922D1 (de) * 2000-10-10 2009-07-16 Univ Oklahoma Vergleichende ligandenabbildung aus mhc-positiven zellen
US20090062512A1 (en) * 2000-10-10 2009-03-05 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US20070099182A1 (en) * 2000-10-10 2007-05-03 Hildebrand William H Comparative ligand mapping from MHC class I positive cells
US20070026433A1 (en) * 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
US20020122820A1 (en) * 2001-01-16 2002-09-05 Hildebrand William H. Soluble MHC artificial antigen presenting cells
US20030054366A1 (en) * 2001-01-23 2003-03-20 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of human colon cancer
WO2002072606A2 (en) * 2001-03-09 2002-09-19 Hildebrand William H Epitope testing using hla
US20040126829A1 (en) * 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
CA2496732A1 (en) * 2002-08-20 2004-03-04 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US7598224B2 (en) * 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US8227411B2 (en) 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
CA2515081A1 (en) * 2003-02-07 2004-08-19 Protein Design Labs, Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
EP1449538A1 (en) * 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation
US20050130897A1 (en) * 2003-12-11 2005-06-16 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
ATE482228T1 (de) * 2004-02-20 2010-10-15 Biosurface Eng Tech Inc Positiver modulator des knochenmorphogenetisches protein-2 (bmp-2)
US20080292629A1 (en) * 2004-05-27 2008-11-27 Yhengbin Yao System Clock Generation Circuit
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
EP2046350A4 (en) 2006-06-22 2011-09-14 Biosurface Eng Tech Inc COMPOSITIONS AND METHOD FOR THE RELEASE OF A BMP-2 AMPLIFIER / COACTIVATOR FOR REINFORCED OSTEOGENESIS
GB0807018D0 (en) * 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
WO2010137012A1 (en) 2009-05-25 2010-12-02 Ramot At Tel-Aviv University Ltd. Peptide therapy for amphiregulin mediated diseases
DE102011056933A1 (de) * 2011-12-22 2013-06-27 Bayerische Motoren Werke Aktiengesellschaft Interieurbauteil für ein Kraftfahrzeug
US9675671B2 (en) * 2014-01-12 2017-06-13 Igf Oncology, Llc Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
WO2015148960A1 (en) 2014-03-28 2015-10-01 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof
US20190016754A1 (en) * 2015-11-10 2019-01-17 Proteothera, Inc. Methods of producing and purifying matrix-binding fusion proteins by ion-exchange chromatography
CN117442747A (zh) 2017-05-21 2024-01-26 Igf肿瘤公司 胰岛素样生长因子——用于治疗骨髓增生异常综合症的化学治疗缀合物
CN110531023B (zh) * 2019-10-08 2024-06-14 安徽理工大学 一种薄层色谱分析仪
CN112779209B (zh) * 2019-11-08 2023-01-24 合肥中科普瑞昇生物医药科技有限公司 原代乳腺上皮细胞培养基、培养方法及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5115096A (en) * 1988-04-15 1992-05-19 Oncogen Amphiregulin: a bifunctional growth modulating glycoprotein

Also Published As

Publication number Publication date
DE3902157A1 (de) 1989-07-27
FI890312A (fi) 1989-07-26
GB2214185B (en) 1992-06-17
IL89033A (en) 1994-05-30
NO890299D0 (no) 1989-01-24
SE8900247L (sv) 1989-07-26
CN1038126A (zh) 1989-12-20
IT1229504B (it) 1991-09-03
FI890312A0 (fi) 1989-01-20
IE890207L (en) 1989-07-25
IE61146B1 (en) 1994-10-05
ES2016432A6 (es) 1990-11-01
MY104980A (en) 1994-07-30
NO890299L (no) 1989-07-26
IL89033A0 (en) 1989-08-15
GB8901469D0 (en) 1989-03-15
ATA14789A (de) 1994-11-15
BE1004201A5 (fr) 1992-10-13
GB2214185A (en) 1989-08-31
JPH02104596A (ja) 1990-04-17
SE504554C2 (sv) 1997-03-03
CH681080A5 (el) 1993-01-15
NO177788C (no) 1995-11-22
AU623109B2 (en) 1992-05-07
NO177788B (no) 1995-08-14
FR2628109A1 (fr) 1989-09-08
GR890100037A (en) 1990-01-31
AU2876989A (en) 1989-08-24
YU16989A (en) 1991-10-31
IT8919186A0 (it) 1989-01-25
AT399720B (de) 1995-07-25
HUT52545A (en) 1990-07-28
FR2628109B1 (fr) 1993-04-09
SE8900247D0 (sv) 1989-01-24
DK29989A (da) 1989-07-26
US5830995A (en) 1998-11-03
DK29989D0 (da) 1989-01-24
NL8900178A (nl) 1989-08-16
NZ227729A (en) 1992-02-25

Similar Documents

Publication Publication Date Title
GR1000849B (el) Αμφιρεγκουλινη:μια νεα διλειτουργικη ρυθμιστικη της αναπτυξης γλυκοπρωτεινη & μεθοδοι παρασκευης.
US4632980B1 (el)
GR1000455B (el) Μεθοδος για την παρασκευη πεπτιδιου-2 που ενεργοποιει ουδετεφιλα.
ES2094159T3 (es) Produccion de factor de crecimiento de celulas endoteliales vasculares.
DOP1981004064A (es) Interferones leucocitarios hibridos para uso en el tratamiento de enfermedades neoplasticas virales.
CY1106798T1 (el) Ανθρωπινα μεσεγχυματικα βλαστοκυτταρα απο περιφερειακο αιμα
ATE221083T1 (de) Glialmitogene faktoren, ihre herstellung und verwendung
ATE65505T1 (de) Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate.
ES2056180T3 (es) Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
ATE49600T1 (de) Kristallinisches kalzium-pseudomonat und verwendung.
NO885275D0 (no) VaskulŸre antikoagulantproteiner, dna'er som koder for dem, fremstilling og anvendelse derav.
DE69435218D1 (de) Regulation der Genexpression von bcl-2
PT88275A (pt) Processo para a preparacao de composicoes farmaceuticas contendo 5-amino ou amino substituido-1,2,3-triazois uteis como agentes antiproliferativos
DE69219590D1 (de) BPC-Peptide, deren Herstellung und Verwendung
ES2001003A4 (es) Metodo para preparar polimeros de sulfometil-poliacrilamidas.
ATE95564T1 (de) Aeusseres membranprotein f von pseudomonas aeruginosa.
GR880100775A (el) Παράγοντας ενεργοποιήσεως ουδετεροφίλων.
ATE99669T1 (de) N-2,3-butadienyl-tri-aminoalkanderivate.
ES2179204T3 (es) Hidrazinas 2-aminocarbonil-1,2-bis(metilsulfonil)-1-sustituidas antitumorales.
ES2130415T3 (es) Linfocitos t tumoricidas.
NO932101L (no) Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker
FI890342A0 (fi) Hjaernmitogener, som binds till heparin.
DE3864356D1 (de) Katalysatoren auf basis von ionerde, ihre herstellung und ihre verwendung.
ES2062267T3 (es) Uso de quinolil- e isoquinolil-oxazol-2-onas para la produccion de un medicamento para el tratamiento de tumores resistentes a multiples farmacos.
CZ112695A3 (en) Polypeptide and use thereof